Wenqi Jiang

Oct 1, 2024 | jitc.bmj.com | Zhiming Li |Wenqi Jiang |Hui Zhou |Hong Cen

MethodsThis was a multicenter, double-blind, randomized phase 3 clinical trial, in which eligible patients were assigned randomly in a 2:1 ratio to either the Hi-CHOP group or the R-CHOP group to receive six cycles of either zuberitamab or rituximab plus conventional CHOP treatment. Patients ranged in age from 18 to 75 years, and a survival time of >6 months was anticipated.